This is the authors' abstract. We don't add key points for this paper.
Background we aimed to assess long-term immunogenicity of the recombinant adenovirus 26 and 5 vector-based COVID-19 vaccine Gam-COVID-Vac (Sputnik V, developed by N.F. Gamaleya National Research Centre, Russia) in patients receiving maintenance hemodialysis compared to healthy subjects. Methods a prospective cohort study included patients treated with maintenance hemodialysis (n = 23) and healthy volunteers (n = 28). The levels of anti-severe acute respiratory syndrome coronavirus-2 specific IgG as well as specific T-cell responses were quantified in all participants at two time points: 1 and 6 months after complete vaccination. All participates were adults, had been vaccinated twice with Gam-COVID-Vac and had no prior history of confirmed COVID-19. Results In both groups, IgG levels decreased from month 1 to 6, however, antibodies did not decline more rapidly in the hemodialysis group (analysis of variance p = 0.7214 for the “time × group” interaction, non-adjusted model). At the end of the study, 48% of non-hemodialysis and 67% of hemodialysis participants showed T-cell positivity. T-spot counts dropped over time in non-hemodialysis controls, but not in hemodialysis subjects (p = 0.008 and p = 0.18, respectively). Conclusions Patients receiving hemodialysis maintain significant long-term humoral response after Gam-COVID-Vac vaccination, which is comparable to that in subjects with normal kidney function. Cellular response turned up to be more sustained over time in hemodialysis group.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Parshina et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: